BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company, announced today an agreement with Amzell B.V. (Amzell) that will further strengthen its position in the marketplace with the commercial rights to one of Amzell’s leading clinical-stage programs that will bring a critical and accessible therapy for patients in need. Under this agreement Amzell will complete the full clinical development of the product in specific markets and Amring will commercialize the product. Amring will invest an undisclosed amount in the development through the clinical phase and FDA approval process.
“With the completion of this agreement and the acquisition of broad commercial rights, Amring is rapidly expanding its position as an important leader in bringing critical and affordable treatments for patients. This agreement will significantly expand our commercial presence in the USA and several regions globally,” stated Daniel Carbery, President and CEO of Amring. “We believe that this brings long term value to patients and customers in our target markets.”
Dario Carrara, PhD., Amzell’s CEO stated, “We are excited to work with Amring to bring this product to the market and into extensive clinical use to meet critical patient needs. This program is one of our top priorities, and we expect to enter into the advanced phase of our clinical trial program rapidly and efficiently.”
About Amring Pharmaceuticals…
